Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

Latest Patents Assigned to Enanta Pharmaceuticals, Inc.

Macrocyclic antiviral agents
Patent number: 11970502
Abstract: The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 30, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Jiajun Zhang, Xiaowen Peng, Yat Sun Or

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
Patent number: 11958879
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Type: Grant
Filed: May 19, 2021
Date of Patent: April 16, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc